FDA-cleared profile

LumiNE US; Lumi

Augmedit B.V. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: LumiNE converts adult CT or contrast-enhanced T1 MR images into reviewed three-dimensional models and displays two- and three-dimensional images in a browser or Microsoft HoloLens 2 for preoperative planning, not diagnosis.

Clinical role
Preoperative CT or MR segmentation, 3D model review, and mixed-reality visualization.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: LumiNE converts adult CT or contrast-enhanced T1 MR images into reviewed three-dimensional models and displays two- and three-dimensional images in a browser or Microsoft HoloLens 2 for preoperative planning, not diagnosis.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: Adult CT or contrast-enhanced T1 MR DICOM images; STL models can be associated with the source scan in supported workflows.
  • Who uses it?Intended users: Neurosurgeons, neurosurgical residents, and hospital-qualified medical professionals preparing imaging for surgeons.
  • What does the software produce?Output: Reviewed 3D models of skin, brain, tumor, and ventricles plus 2D/3D browser or HoloLens visualization.
  • What is its most important limitation?Key limitation: Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.

Clinical takeaway. Clinical role: LumiNE converts adult CT or contrast-enhanced T1 MR images into reviewed three-dimensional models and displays two- and three-dimensional images in a browser or Microsoft HoloLens 2 for preoperative planning, not diagnosis.

Evidence takeaway. Evidence from the reviewed source record: Exact-submission U.S. testing used independent expert-truthed MR cases. Median Dice and 95% Hausdorff results met prespecified criteria for brain, skin, tumor, and ventricles; subgroup findings directly produced the single-tumor size limits. A later phantom crossover study is product-family workflow evidence only.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
LumiNE converts adult CT or contrast-enhanced T1 MR images into reviewed three-dimensional models and displays two- and three-dimensional images in a browser or Microsoft HoloLens 2 for preoperative planning, not diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Preoperative CT or MR segmentation, 3D model review, and mixed-reality visualization.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Adult CT or contrast-enhanced T1 MR DICOM images; STL models can be associated with the source scan in supported workflows.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Reviewed 3D models of skin, brain, tumor, and ventricles plus 2D/3D browser or HoloLens visualization.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Preoperative planning environments for adults aged 22 years or older.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Neurosurgeons, neurosurgical residents, and hospital-qualified medical professionals preparing imaging for surgeons.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
Exact-submission U.S. testing used independent expert-truthed MR cases. Median Dice and 95% Hausdorff results met prespecified criteria for brain, skin, tumor, and ventricles; subgroup findings directly produced the single-tumor size limits. A later phantom crossover study is product-family workflow evidence only.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact-submission U.S. testing used independent expert-truthed MR cases. Median Dice and 95% Hausdorff results met prespecified criteria for brain, skin, tumor, and ventricles; subgroup findings directly produced the single-tumor size limits. A later phantom crossover study is product-family workflow evidence only.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Brain median Dice

0.96 DSC

  • EndpointBrain segmentation
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Skin median Dice

0.99 DSC

  • EndpointSkin segmentation
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Tumor median Dice

0.93 DSC

  • EndpointSingle eligible intracranial tumor segmentation
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Ventricle median Dice

0.89 DSC

  • EndpointVentricle segmentation
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Brain median HD95

5.88 mm

  • EndpointBrain boundary distance
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Skin median HD95

3.36 mm

  • EndpointSkin boundary distance
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Tumor median HD95

2.85 mm

  • EndpointTumor boundary distance
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

Ventricle median HD95

1.93 mm

  • EndpointVentricle boundary distance
  • PopulationLumiNE US; Lumi
  • Tested versionLumiNE US / Lumi cleared in K240094

K240094 FDA performance package for LumiNE US; Lumi

  • DesignManufacturer independent U.S. MR segmentation validation against consensus reference standards from three U.S. neurosurgeons
  • PopulationAdults with contrast-enhanced T1 brain MRI and eligible known intracranial tumors
  • Scopeexact submission
  • Tested versionLumiNE US / Lumi cleared in K240094
  • IndependenceSponsor or vendor study

K240094

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Mixed-reality preoperative planning with Lumi

  • DesignPhantom crossover evaluation
  • PopulationSimulated neurosurgical planning tasks
  • Scopeproduct family
  • Tested versionLumi product family; exact K240094 build not established
  • IndependenceIndependent study

PMC12743098

Product-family workflow evidence in a simulated setting, not clinical outcome evidence.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K240094 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult CT or contrast-enhanced T1 MR DICOM images; STL models can be associated with the source scan in supported workflows.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K240094: LumiNE US; Lumi

  2. Routing

    Source context, not route validation: DICOM and supported STL ingestion with browser and HoloLens 2 visualization; test scanners, DICOM variants, dimensional fidelity, latency, and export or revision behavior.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K240094: LumiNE US; Lumi · LumiNE FDA clearance announcement · Mixed-reality preoperative planning with Lumi in a phantom crossover study

  3. AI processing

    Source context, not route validation: Secure cloud storage and browser-based viewer with optional Microsoft HoloLens 2, as described in K240094.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K240094: LumiNE US; Lumi · LumiNE FDA clearance announcement · Mixed-reality preoperative planning with Lumi in a phantom crossover study

  4. Returned objects

    Source context, not route validation: Reviewed 3D models of skin, brain, tumor, and ventricles plus 2D/3D browser or HoloLens visualization.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K240094: LumiNE US; Lumi

  5. Viewer/worklist/report

    Unresolved route: Reviewed 3D models of skin, brain, tumor, and ventricles plus 2D/3D browser or HoloLens visualization.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K240094: LumiNE US; Lumi

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Secure cloud storage and browser-based viewer with optional Microsoft HoloLens 2, as described in K240094.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM and supported STL ingestion with browser and HoloLens 2 visualization; test scanners, DICOM variants, dimensional fidelity, latency, and export or revision behavior.
  • Exact FDA submission
  • Checked 2026-09-03
Security
K240094 describes a secure cloud environment and anonymizer. Obtain current encryption, identity, audit, retention, support-access, backup, data-residency, and incident-response details.
  • Exact FDA submission
  • Checked 2026-09-03

Confirm the controls against the exact contracted architecture and release.

Training
Only neurosurgeons, neurosurgical residents, and hospital-qualified medical professionals preparing imaging for surgeons. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K240094 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM and supported STL ingestion with browser and HoloLens 2 visualization; test scanners, DICOM variants, dimensional fidelity, latency, and export or revision behavior.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240094
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication specifies MRI and/or CT imaging of adult patients; it does not support the broader directory-style modality value. Controlled directory display reconciled from exact FDA wording: Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT) imaging of adult patients. -> Radiological images; modality varies or is not specified in FDA list.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-09-10
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K240094: LumiNE US; Lumi

    U.S. Food and Drug Administration - Published 2024-09-10 - Accessed 2026-09-19

    Scope: purpose, anatomy, intendedUsers, input, output, limitations, modality, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. LumiNE FDA clearance announcement

    Augmedit - Accessed 2026-09-03

    Scope: productFamily, workflowRole, deployment, implementationCapabilities, currentCommercialContext

  8. Mixed-reality preoperative planning with Lumi in a phantom crossover study

    Journal of Neuro-Oncology - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, implementationCapabilities, monitoring

Research history

  1. K240094 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K192304

SIS Software Version 3.6.0

Surgical Information Sciences, Inc.

Authorized purpose: SIS Software v3.6.0 displays, presents, documents, registers, fuses, and processes brain MR and postoperative CT images to support stereotactic neurosurgery and subthalamic-nucleus visualization.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2019-09-13

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history